Clinical Trials
44 trialsAuto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R
City of Hope Medical Center
AML1208
Gruppo Italiano Malattie EMatologiche dell'Adulto
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
Children's Oncology Group
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia
Children's Oncology Group
Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy
Fred Hutchinson Cancer Center
Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy
Case Comprehensive Cancer Center
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
University of Maryland, Baltimore
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
University of Maryland, Baltimore
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
M.D. Anderson Cancer Center
Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Wake Forest University Health Sciences
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia
National Cancer Institute (NCI)
AML1107
Gruppo Italiano Malattie EMatologiche dell'Adulto
A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia
Wake Forest University Health Sciences
Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia
Eastern Cooperative Oncology Group
Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia
Children's Oncology Group
Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531
Children's Oncology Group
Study to Predict Risk of Relapse in Bone Marrow Cell Samples From Younger Patients With Acute Myeloid Leukemia
Children's Oncology Group
S0106A, Biomarkers in Samples From Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Cytarabine-Based Chemotherapy
SWOG Cancer Research Network
S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML
SWOG Cancer Research Network
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
University Health Network, Toronto
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
National Cancer Institute (NCI)
S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
SWOG Cancer Research Network
S0106B Studying Bone Marrow Samples From Women With Acute Myeloid Leukemia
SWOG Cancer Research Network
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
National Cancer Institute (NCI)
Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
Roswell Park Cancer Institute
Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia
University of Rochester
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
National Cancer Institute (NCI)
Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer
Memorial Sloan Kettering Cancer Center
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
National Cancer Institute (NCI)
Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
National Cancer Institute (NCI)
XK469R in Treating Patients With Refractory Hematologic Cancer
National Cancer Institute (NCI)
Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
National Institutes of Health Clinical Center (CC)
Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins